Physician profile
Edwin Dejesus
NPI 1295734101
$41,518.94
in general payments reported to CMS, 2019-2025
21 companies · $766 in 2025
The $766 reported for 2025 was more than what 75% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $1,370 · 2021: $4,126 · 2022: $8,617 · 2023: $536 · 2024: $782 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,051 · Education: $32.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,051.35 |
| Education | $32.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $22,007.17 | 2019-2025 | |
| Viiv Healthcare Company | $7,837.69 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Theratechnologies INC. | $5,698.68 | 2019-2025 | Trogarzo, Egrifta |
| Janssen Scientific Affairs, LLC | $4,233.64 | 2019 | |
| Janssen Biotech, INC. | $704.97 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $548.38 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Abbvie INC. | $111.53 | 2020-2024 | Mavyret |
| Hologic Sales and Service, LLC | $77.77 | 2023-2024 | Aptima, Thinprep 2000 Processor |
| Emd Serono, INC. | $60.06 | 2019 | |
| Insmed, INC. | $48.72 | 2021-2024 | Arikayce |
| Kerecis Limited | $43.65 | 2021-2022 | |
| Allergan, INC. | $30.99 | 2019-2020 | |
| Janssen Products, LP | $29.99 | 2019 | |
| Napo Pharmaceuticals INC | $20.34 | 2025 | Mytesi |
| Aytu Biopharma, INC. | $19.46 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $17.18 | 2023 | Shingrix |
| Seqirus USA INC | $16.01 | 2019 | |
| Amarin Pharma, INC. | $12.71 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Dejesus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.